173 related articles for article (PubMed ID: 7222314)
1. Urine composition in patients with urolithiasis during treatment with magnesium oxide.
Tiselius HG; Ahlstrand C; Larsson L
Urol Res; 1980; 8(4):197-206. PubMed ID: 7222314
[TBL] [Abstract][Full Text] [Related]
2. A biochemical basis for grouping of patients with urolithiasis.
Tiselius HG; Almgård LE; Larsson L; Sörbo B
Eur Urol; 1978; 4(4):241-9. PubMed ID: 668734
[TBL] [Abstract][Full Text] [Related]
3. Urine composition in patients with renal stone disease during treatment with allopurinol.
Tiselius HG; Larsson L
Scand J Urol Nephrol; 1980; 14(1):65-71. PubMed ID: 7375845
[TBL] [Abstract][Full Text] [Related]
4. Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis.
Takasaki E
Invest Urol; 1975 Jan; 12(4):251-4. PubMed ID: 1112654
[TBL] [Abstract][Full Text] [Related]
5. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
[TBL] [Abstract][Full Text] [Related]
6. [Clinical studies on the recurrence of urolithiasis: (1). Influence of diet on urinary excretion of the stone forming constituents].
Murayama T; Taguchi H
Hinyokika Kiyo; 1987 Sep; 33(9):1321-30. PubMed ID: 3434487
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers.
Rattan V; Sidhu H; Vaidyanathan S; Thind SK; Nath R
Urol Res; 1994; 22(3):161-5. PubMed ID: 7992461
[TBL] [Abstract][Full Text] [Related]
8. [Clinical studies of the recurrence of urolithiasis (3). Influence of sodium intake on urinary excretion of calcium, uric acid, oxalate, phosphate and magnesium].
Murayama T; Taguchi H
Hinyokika Kiyo; 1988 Sep; 34(9):1537-41. PubMed ID: 3213789
[TBL] [Abstract][Full Text] [Related]
9. Validity of biochemical findings in the evaluation of patients with urolithiasis.
Tiselius HG; Larsson L
Eur Urol; 1980; 6(2):90-4. PubMed ID: 7358065
[TBL] [Abstract][Full Text] [Related]
10. Biochemical risk factors for stone formation in a Scottish paediatric hospital population.
MacDougall L; Taheri S; Crofton P
Ann Clin Biochem; 2010 Mar; 47(Pt 2):125-30. PubMed ID: 20144971
[TBL] [Abstract][Full Text] [Related]
11. Comparison of urinary oxalate excretion in urolithiasis patients with and without hypercalciuria.
Koide T; Bowyer RC; Brockis JG
Br J Urol; 1985 Oct; 57(5):505-9. PubMed ID: 4063729
[TBL] [Abstract][Full Text] [Related]
12. Urine composition following jejunoileal bypass.
Nordenvall B; Backman L; Larsson L; Tiselius HG
Eur Urol; 1983; 9(1):35-9. PubMed ID: 6822241
[TBL] [Abstract][Full Text] [Related]
13. Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and magnesium oxide.
Ahlstrand C; Tiselius HG
Br J Urol; 1984 Apr; 56(2):125-30. PubMed ID: 6498431
[TBL] [Abstract][Full Text] [Related]
14. Changes in urinary composition of calcium oxalate stone formers.
Rahman B; Rahman MA
Biomed Pharmacother; 1986; 40(3):108-10. PubMed ID: 3742009
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease.
Farmer RG; Mir-Madjlessi SH; Kiser WS
Cleve Clin Q; 1974; 41(3):109-17. PubMed ID: 4416806
[No Abstract] [Full Text] [Related]
16. Proceedings: Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease and relationship to urolithiasis.
Farmer RG; Mir-Madjlessi SH; Kiser WS
Gut; 1973 Oct; 14(10):828. PubMed ID: 4758698
[No Abstract] [Full Text] [Related]
17. [Hydrochlorothiazide, allopurinol and magnesium oxide in the treatment of recurrent calcium urolithiasis].
Musialik D; Głuszek J; Pieczyńska A
Pol Tyg Lek; 1991 Oct 7-21; 46(40-42):739-42. PubMed ID: 1669148
[TBL] [Abstract][Full Text] [Related]
18. Female stone disease: the changing trend.
Marickar YM; Vijay A
Urol Res; 2009 Dec; 37(6):337-40. PubMed ID: 19779708
[TBL] [Abstract][Full Text] [Related]
19. The role of overweight and obesity in calcium oxalate stone formation.
Siener R; Glatz S; Nicolay C; Hesse A
Obes Res; 2004 Jan; 12(1):106-13. PubMed ID: 14742848
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.
Ahlstrand C; Tiselius HG
J Urol; 1981 Nov; 126(5):635-9. PubMed ID: 7299925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
